Advances in quantitative PCR technology: 5′ nuclease assays

YS Lie, CJ Petropoulos - Current opinion in biotechnology, 1998 - Elsevier
The development of 5′ nuclease assays represents a significant advance in nucleic acid
quantitation. This approach utilizes the 5′-3′ exonuclease activity of Thermus aquaticus …

Assessing chemokine co-receptor usage in HIV

E Coakley, CJ Petropoulos… - Current opinion in …, 2005 - journals.lww.com
Current Opinion in Infectious Diseases Log in or Register Subscribe to journalSubscribe Get
new issue alertsGet alerts Secondary Logo Journal Logo Advanced Search Toggle navigation …

[HTML][HTML] Multiple early factors anticipate post-acute COVID-19 sequelae

Y Su, D Yuan, DG Chen, RH Ng, K Wang, J Choi, S Li… - Cell, 2022 - cell.com
Post-acute sequelae of COVID-19 (PASC) represent an emerging global crisis. However,
quantifiable risk factors for PASC and their biological associations are poorly resolved. We …

A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1

CJ Petropoulos, NT Parkin, KL Limoli… - Antimicrobial agents …, 2000 - journals.asm.org
Although combination antiretroviral therapy has resulted in a considerable improvement in
the treatment of human immunodeficiency virus (HIV) type 1 (HIV-1) infection, the …

Rapid evolution of the neutralizing antibody response to HIV type 1 infection

DD Richman, T Wrin, SJ Little… - Proceedings of the …, 2003 - pnas.org
A recombinant virus assay was used to characterize in detail neutralizing antibody
responses directed at circulating autologous HIV in plasma. Examining serial plasma …

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies

JM Binley, T Wrin, B Korber, MB Zwick, M Wang… - Journal of …, 2004 - journals.asm.org
Broadly neutralizing monoclonal antibodies (MAbs) are potentially important tools in human
immunodeficiency virus type 1 (HIV-1) vaccine design. A few rare MAbs have been …

Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia

SG Deeks, T Wrin, T Liegler, R Hoh… - … England Journal of …, 2001 - Mass Medical Soc
Background In many patients with human immunodeficiency virus (HIV) infection, therapy
with potent antiretroviral drugs does not result in complete suppression of HIV replication …

Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy

F Pereyra, MM Addo, DE Kaufmann… - The Journal of …, 2008 - academic.oup.com
Background. Spontaneous control of human immunodeficiency virus (HIV) infection has
been documented in a minority of HIV-infected individuals. The mechanisms behind this …

Chronic viral coinfections differentially affect the likelihood of developing long COVID

MJ Peluso, TM Deveau, SE Munter, D Ryder… - The Journal of clinical …, 2023 - jci.org
BACKGROUND The presence and reactivation of chronic viral infections, such as EBV,
CMV, and HIV, have been proposed as potential contributors to long COVID (LC), but …

Adaptor plasmids simplify the insertion of foreign DNA into helper-independent retroviral vectors

SH Hughes, JJ Greenhouse, CJ Petropoulos… - Journal of …, 1987 - journals.asm.org
We have previously described several helper independent vector constructions (S. Hughes
and E. Kosik, Virology 136: 89-99, 1984; J. Sorge and SH Hughes, J. Mol. Appl. Genet. 1 …